INDIVIOR ORD USD0.50 news, videos and press releases
For more news please use our advanced search feature.
INDIVIOR ORD USD0.50 - More news...
INDIVIOR ORD USD0.50 - More news...
- New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting
- INVVY CLASS ACTION ALERT: Rosen Law Firm Files Securities Class Action Against Indivior PLC - INVVY
- Bernstein Liebhard LLP Announces That Approximately Seven Weeks Remain To Make A Motion For Lead Plaintiff In A Class Against Indivior PLC
- INDIVIOR SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Indivior PLC - INVVY
- Indivior First Quarter 2019 Results Now Available; Conference Call With Leadership Today
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Indivior PLC Investors (INVVY)
- INVVY CLASS ACTION ALERT: Hagens Berman Alerts Indivior PLC (INVVY) Investors to Securities Fraud Class Action, Encourages Investors With Losses in Excess of $50,000 to Contact the Firm
- LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm
- Johnson Fistel Announces Class Action Suit against Indivior PLC (INVVY); Encourages Investors to Contact the Firm for Additional Information
- Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, Duluth Holdings, Inc., Establishment Labs Holdings Inc., Flex Ltd., Global Brass and Copper Holdings, Inc., Indivior PLC, Papa Murphy's Holdings, Inc., and Zogenix, Inc.
- Hagens Berman Alerts Indivior PLC (INVVY) Investors of the Firm's Investigation of Possible Securities Law Violations
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INVVY
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INVVY
- Statement of Indivior on Grand Jury Indictment
- Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference
- Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later
- Indivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults
- Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
- Indivior FY 2018 Financial Results
- Indivior Publishes Design and Patient Characteristics for Real-World Study of Life Changes in People Treated with SUBLOCADE™ (Buprenorphine Extended-Release) in Contemporary Clinical Trials
- Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling
- Indivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019
- Indivior Announces Health Canada Approval of SUBLOCADETM (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
- Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film
- PERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults
- Indivior Announces Upcoming Investor Events
- Indivior Announces Nine Month and Third Quarter 2018 Results
- Indivior Applauds Enactment of the SUPPORT for Patients and Communities Act of 2018
- Indivior Provides Update on Key Business Drivers and Expectations
- Indivior Prepays $150 Million of Outstanding Debt
